Global Women Healthcare Market Overview
According to SPER Market Research, the Global Women Healthcare Market is estimated to reach USD 56.24 billion by 2033 with a CAGR of 13.46%.
The global women's healthcare market refers to the market for women's health and well-being products and services. This comprises a wide range of medical devices, medications, and services addressing women's health issues from adolescence to menopause and beyond. The women's healthcare market encompasses reproductive health products and services such as contraception and fertility treatments, as well as general health and wellness products and services such as breast cancer screening, menopausal management, and osteoporosis therapy.
Exploring the Growth Drivers of the Global Women Healthcare Industry.
The global women's healthcare market is being pushed by factors such as the rising prevalence of chronic diseases among women, increased awareness and focus on women's health, and rising healthcare expenditure. Social, economic, and cultural issues such as changing lifestyles, more urbanization, and the growing number of working women all have an impact on the market. Diabetes, cardiovascular disease, and cancer are becoming more common among women worldwide. This has boosted the demand for healthcare products and services linked to the prevention, diagnosis, and treatment of these disorders. Furthermore, there has been an increasing global awareness and focus on women's health, spurred by initiatives by governments, non-profit groups, and healthcare professionals. This has resulted in greater investment in research and development of women's healthcare goods and services. Global healthcare spending is rising due to rising incomes, aging populations, and increased demand for healthcare services. As a result, spending on women's healthcare products and services has soared.
-008511517052023.jpg)
What challenges does the Global Women Healthcare Market face?
The global market for women's healthcare confronts a number of issues, including inadequate access to healthcare. Women continue to have restricted access to healthcare in many regions of the world, particularly in rural areas and low-income countries. This may impede their ability to access adequate health-care services. Furthermore, in some countries, women may experience stigma and prejudice because of their health demands, which can hinder them from seeking care or receiving appropriate treatments. Healthcare expenditures can be a substantial obstacle for women, especially in nations where universal healthcare coverage does not exist. This can make it difficult for them to obtain critical treatments and preventive care.
In what ways has the COVID-19 pandemic affected Global Women Healthcare Market?
The COVID-19 pandemic has had a number of effects on the worldwide women's healthcare business, including supply chain disruption. Global supply chains, especially those for women's healthcare products and services, have been impacted by the pandemic. This has resulted in supply shortages, including contraception and menstruation products. Many normal and elective healthcare services, particularly women's healthcare, have been delayed or cancelled as healthcare systems focus on responding to the pandemic. As a result, fewer women are seeking care for reproductive health and other health conditions. The epidemic has made access to contraception more difficult for women, leading to an increase in unwanted pregnancies and unsafe abortions in some locations.
-008512117052023.jpg)
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Drug, By Application
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | Agile Therapeutics Inc., Allergan, Amgen, Apthoecus Pharmaceutical, Bayer AG, Blairex Laboratories, Eli Lilly and Company, Ferring Pharmaceuticals, Johnson & Johnson, Lupin, Merck & Co., Mylan N.V., Novartis AG, Pfizer Inc., Others
|
Key Target Audience
- Government and Regulatory Bodies
- Healthcare Providers and Organizations
- Investors and Financial Analysts
- Pharmaceutical and Biotech Companies
- Research and Academic Institutions
Global Women Healthcare Market Segmentation:
1. By Drug:
- Global Women Healthcare Market Value Share and Forecast, By Drug, 2023-2033
- ACTONEL
- EVISTA
- FORTEO
- Minastrin 23 Fe
- Mirena
- NuvaRing
- ORTHO TRI-CY LO (28)
- Premarin
2. By Application:
- Global Women Healthcare Market Value Share and Forecast, By Application, 2023-2033
- Contraceptive
- Endometriosis
- Hormonal Infertility
- Menopause
- Polycystic Ovary Syndrome
- Postmenopausal Osteoporosis
- Other Applications
5. By Region:
- Asia-Pacific
- Europe
- Middle East & Africa
- North America
- Latin America
Key Topics Covered in the Report
- Global Women Healthcare Market Size (FY’2023-FY’2033)
- Overview of Global Women Healthcare Market
- Segmentation of Global Women Healthcare Market By Drug (ACTONEL, EVISTA, FORTEO, Minastrin 23 Fe, Mirena, NuvaRing, ORTHO TRI-CY LO (28), Premarin, Prolia, Reclast/Aclasta, XGEVA, Zometa)
- Segmentation of Global Women Healthcare Market By Application (Contraceptive, Endometriosis, Hormonal Infertility, Menopause, Polycystic Ovary Syndrome, Postmenopausal Osteoporosis, Other Applications)
- Statistical Snap of Global Women Healthcare Market
- Growth Analysis of Global Women Healthcare Market
- Problems and Challenges in Global Women Healthcare Market
- Competitive Landscape in the Global Women Healthcare Market
- Impact of COVID-19 and Demonetization on Global Women Healthcare Market
- Details on Recent Investment in Global Women Healthcare Market
- Competitive Analysis of Global Women Healthcare Market
- Key Players in the Global Women Healthcare Market
- SWOT Analysis of Global Women Healthcare Market
- Global Women Healthcare Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Women Healthcare Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Women Healthcare Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Women Healthcare Market
7. Global Women Healthcare Market, By Drug (USD Million)
7.1. Global Women Healthcare Market Value Share and Forecast, By Drug, 2023-2033
7.2. ACTONEL
7.3. EVISTA
7.4. FORTEO
7.5. Minastrin 23 Fe
7.6. Mirena
7.7. NuvaRing
7.8. ORTHO TRI-CY LO (28)
7.9. Premarin
7.10. Prolia
7.11. Reclast/Aclasta
7.12. XGEVA
7.13. Zometa
8. Global Women Healthcare Market, By Application (USD Million)
8.1. Global Women Healthcare Market Value Share and Forecast, By Application, 2023-2033
8.2. Contraceptive
8.3. Endometriosis
8.4. Hormonal Infertility
8.5. Menopause
8.6. Polycystic Ovary Syndrome
8.7. Postmenopausal Osteoporosis
8.8. Other Applications
9. Global Women Healthcare Market Forecast, 2019-2033 (USD Million)
9.1. Global Women Healthcare Market Size and Market Share
10. Global Women Healthcare Market, By Drug, 2019-2033 (USD Million)
10.1. Global Women Healthcare Market Size and Market Share By Drug (2019-2026)
10.2. Global Women Healthcare Market Size and Market Share By Drug (2027-2033)
11. Global Women Healthcare Market, By Application, 2019-2033 (USD Million)
11.1. Global Women Healthcare Market Size and Market Share By Application (2019-2026)
11.2. Global Women Healthcare Market Size and Market Share By Application (2027-2033)
12. Global Women Healthcare Market, By Region, 2019-2033 (USD Million)
12.1. Global Women Healthcare Market Size and Market Share By Region (2019-2026)
12.2. Global Women Healthcare Market Size and Market Share By Region (2027-2033)
12.3. Asia-Pacific
12.3.1. Australia
12.3.2. China
12.3.3. India
12.3.4. Japan
12.3.5. South Korea
12.3.6. Rest of Asia-Pacific
12.4. Europe
12.4.1. France
12.4.2. Germany
12.4.3. Italy
12.4.4. Spain
12.4.5. United Kingdom
12.4.6. Rest of Europe
12.5. Middle East and Africa
12.5.1. Kingdom of Saudi Arabia
12.5.2. United Arab Emirates
12.5.3. Rest of Middle East & Africa
12.6. North America
12.6.1. Canada
12.6.2. Mexico
12.6.3. United States
12.7. Latin America
12.7.1. Argentina
12.7.2. Brazil
12.7.3. Rest of Latin America
13. Company Profile
13.1. Agile Therapeutics Inc.
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Allergan
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Amgen
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Apthoecus Pharmaceutical
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Bayer AG
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Blairex Laboratories
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Eli Lilly And Company
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Ferring Pharmaceuticals
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Johnson & Johnson
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Lupin
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Merck & Co.
13.11.1. Company details
13.11.2. Financial outlook
13.11.3. Product summary
13.11.4. Recent developments
13.12. Mylan N.V.
13.12.1. Company details
13.12.2. Financial outlook
13.12.3. Product summary
13.12.4. Recent developments
13.13. Novartis AG
13.13.1. Company details
13.13.2. Financial outlook
13.13.3. Product summary
13.13.4. Recent developments
13.14. Pfizer Inc.
13.14.1. Company details
13.14.2. Financial outlook
13.14.3. Product summary
13.14.4. Recent developments
13.15. Others
14. List of Abbreviations
15. Reference Links
16. Conclusion
17. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
